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Background: A sophisticated level of coordinated gene expression is necessary for skeletal muscle fibers to obtain
their unique functional identities. We have previously shown that the transcription factor Sox6 plays an essential
role in coordinating muscle fiber type differentiation by acting as a transcriptional suppressor of slow fiber-specific
genes. Currently, mechanisms regulating the activity of Sox6 in skeletal muscle and how these mechanisms affect
the fiber phenotype remain unknown.
Methods: Yeast two-hybrid screening was used to identify binding partners of Sox6 in muscle. Small interfering
RNA (siRNA)-mediated knockdown of one of the Sox6 binding proteins, Trip12, was used to determine its effect on
Sox6 activity in C2C12 myotubes using quantitative analysis of fiber type-specific gene expression.
Results: We found that the E3 ligase Trip12, a HECT domain E3 ubiquitin ligase, recognizes and polyubiquitinates
Sox6. Inhibiting Trip12 or the 26S proteasome activity resulted in an increase in Sox6 protein levels in C2C12
myotubes. This control of Sox6 activity in muscle cells via Trip12 ubiquitination has significant phenotypic
outcomes. Knockdown of Trip12 in C2C12 myotubes led to upregulation of Sox6 protein levels and concurrently to
a decrease in slow fiber-specific Myh7 expression coupled with an increased expression in fast fiber-specific Myh4.
Therefore, regulation of Sox6 cellular levels by the ubiquitin-proteasome system can induce identity-changing
alterations in the expression of fiber type-specific genes in muscle cells.
Conclusions: Based on our data, we propose that in skeletal muscle, E3 ligases have a significant role in regulating
fiber type-specific gene expression, expanding their importance in muscle beyond their well-established role in
atrophy.
Keywords: Sox6, Skeletal muscle, Fiber type differentiation, Trip12, E3 ubiquitin ligase, HECT domain, Ubiquitin-
proteasome systemBackground
Mammalian skeletal muscles consist of functionally het-
erogeneous myofibers, which can be broadly classified
into two groups, slow-twitch and fast-twitch fibers. They
differ in contraction speed, metabolic capacity, fatigue
resistance, sensitivity to calcium, and a variety of other
attributes [1-3]. This physiologic diversity among muscle
fibers is the outward manifestation of the concerted
expression of hundreds of genes unique to each fiber* Correspondence: nhagiwara@ucdavis.edu
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reproduction in any medium, provided the ortype [4], culminating in the specific biochemical charac-
teristics of either fast fiber or slow fiber type. Despite its
significance to muscle physiology and muscle degenera-
tive diseases (e.g., exercise physiology [5]; Duchenne
muscular dystrophy [6,7]; inflammatory atrophy [8]),
knowledge regarding the molecular mechanisms orches-
trating this coordinated expression exists only in vague
outlines.
Our recent studies demonstrated that the transcription
factor Sox6 directly suppresses transcription of slow
fiber-specific genes during mouse muscle development
[9,10]. Loss of a functional Sox6 protein in skeletal
muscle results in a dramatic increase in slow fibers inThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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indicate that Sox6 is one of the key factors regulating the
fiber type differentiation of mammalian skeletal muscles.
To uncover how Sox6 activity is controlled in
muscle, we searched for regulatory proteins for Sox6
by performing yeast two-hybrid screening. In this
manuscript, we report identification of the Trip12 E3
ligase as a negative regulator of Sox6 activity. E3 ubi-
quitin ligases determine substrate specificity for ubi-
quitin modification in the ubiquitin-proteasome
system [13] and are involved at all levels of transcrip-
tional regulation [14]. We discovered that in C2C12
myotubes, Sox6 protein levels are controlled by the
ubiquitin-proteasome system in which Sox6 proteins
are polyubiquitinated by Trip12 and degraded by the
26S proteasome. Significant to the orchestrated regula-
tion of muscle fiber phenotype, we found that the sup-
pression of Trip12 levels in C2C12 myotube cultures
results in three interlocking events: increased levels of
Sox6 protein, downregulation of the slow MyHC
isoform (Myh7, MyHC-I/β), and upregulation of the
fast MyHC isoform (Myh4, MyHC-IIb). Our new find-
ing suggests that the ubiquitin-proteasome system
plays a significant role in muscle fiber differentiationFigure 1 SOX6 coiled-coil domain physically interacts with TRIP12 HE
[17]. The coiled-coil (CC) domain containing the leucine-zipper (LZ) motif a
cDNA library. The amino acid sequence of the CC domain is 100% conserv
full-length human TRIP12 protein. The partial TRIP12 cDNA clone identified
domain (aa 1614–2040). (C) Diagrams of the bait and prey expression vecto
for each vector construct. The SOX6 CC-domain was tagged with c-Myc at
C-terminus. (D) Co-IP assays were performed using HEK293 cell lysate trans
lanes contained 2% (10 μg) of un-manipulated lysate. Rabbit polyclonal ant




The MATCHMAKER Two-Hybrid System 3 (Clontech,
Mountain View, CA, USA) was used following the manu-
facture’s protocol. Construction of SOX6 coiled-coil (CC)
domain containing bait plasmid (Figure 1A) was reported
previously [16]. AH-109 yeast cells were first transformed
with the bait plasmid and subsequently with the human
heart cDNA prey plasmid library. Screening was
performed on medium-stringency plates (three selection
markers, histidine, leucine, and tryptophan) following the
manufacturer’s recommendation. Colonies grown to the
size of 2–3 mm in 5 days were streaked on high-
stringency plates (histidine, adenine, β-gal). Seventy-five
large colonies were obtained in this screening, and prey
cDNA plasmids were isolated using the YEASTMAKER
Yeast Plasmid Isolation Kit (Clontech) for sequencing.
Twenty-five of them contained in-frame human protein
sequences recorded in GenBank. Of these, the clone
containing the C-terminus HECT domain of TRIP12
(Figure 1B) was selected for further analysis.CT domain. (A) Schematic representation of the human SOX6 protein
nd Q-box (aa 143–304) was used as bait for screening a human heart
ed between mice and humans. (B) Schematic representation of the
by yeast hybrid screening contained the most C-terminal HECT
rs used for Co-IP. The numbers indicate the amino acid regions used
the C-terminus. The TRIP12 HECT domain was tagged with HSV at the
fected with the bait and prey expression vectors depicted in (C). Input
ibodies used for pull down are listed under IP. Mouse monoclonal
antibody was used as a negative control.
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Mice were maintained and killed according to the ani-
mal protocol approved by the Institutional Animal Care
and Use Committee at the University of California,
Davis, which adheres to the National Institutes of Health
guidelines.Cell culture
HEK293 (human embryonic kidney cell line) and C2C12
(mouse skeletal myoblast cell line) were maintained in
growth medium (GM) consisting of Dulbecco’s modified
Eagle’s medium (DMEM), 10% fetal bovine serum (FBS),
100 U/ml penicillin, and 100 μg/ml streptomycin at 37°C
in a 5% CO2-humidified incubator. To induce myotube
differentiation, C2C12 cells were incubated in differenti-
ation medium (DM) consisting of DMEM, 2% horse
serum, 100 U/ml penicillin, and 100 μg/ml streptomycin.Western blotting and densitometric analysis
Brain, heart, lung, kidney, liver, and skeletal muscle
(gastrocnemius) were harvested from a 2-month-old
wild-type (WT) female mouse, and testis was harvested
from a 2-month-old WT male mouse, respectively. Tis-
sue samples were homogenized in RIPA buffer (1X PBS,
1% Nonidet P40, 0.5% sodium deoxycholate, 0.1% SDS)
supplemented with protease and phosphatase inhibitor
cocktails (Thermo Scientific, Waltham, MA, USA) and
clarified by centrifugation at 17,900g at 4°C for 15 min.
Cultured cell samples were processed as described at
each experimental section below. Protein samples were
resolved on 7.5% or 4-15% gradient SDS-PAGE gels,
transferred to nitrocellulose membranes, and processed
for incubation with appropriate antibodies. Signals were
detected on X-ray films using Pierce ECL Western Blot-
ting Substrate (Thermo Scientific) or Western Lighting
Plus (PerkinElmer, Waltham, MA, USA). For detecting
polyubiquitinated Sox6 protein in vitro and in vivo,
WesternBright Sirius Chemiluminescent HRP substrate
(Advansta, Menlo Park, CA, USA) was used. The follow-
ing primary antibodies were used: Sox6 (ab30455, Abcam,
Cambridge, MA, USA: rabbit polyclonal), TRIP12 (A301-
814A, Bethyl Laboratories, Inc., Montgomery, TX, USA:
rabbit polyclonal), β-actin (sc-1616, Santa Cruz Biotech-
nology, Inc., Santa Cruz, CA, USA: goat polyclonal), TBP
(NB500-700, Novus Biologicals, Littleton, CO, USA:
mouse monoclonal), HA (H3663, Sigma-Aldrich: mouse
monoclonal), c-Myc (R950-25, Invitrogen, Carlsbad,
CA, USA: mouse monoclonal), HSV (69171-4, Novagen,
Madison, WI, USA: mouse monoclonal), anti-
DYKDDDDK (clone L5, 637301, BioLegend, San Diego,
CA, USA: rat monoclonal), and myogenin (clone F5D, De-
velopmental Studies Hybridoma Bank, Iowa City, IA,
USA: mouse monoclonal).Quantification of bands was performed using digital
scans of the exposed films and ImageJ software (http://
imagej.nih.gov/ij/) according to the user guide. Only
films with unsaturated intensity of bands were used for
densitometric analysis. All densitometry measurements
were performed using at least three independent samples,
and statistical significance between control and test sam-
ples was determined by the two-tailed Student’s t-tests.
Co-immunoprecipitation (Co-IP)
Interaction between the human SOX6 CC domain and
the TRIP12 HECT domain was confirmed by Co-IP.
Human SOX6 CC-myc (tagged at the C-terminus) was
constructed by inserting the SOX6 CC cDNA sequence
into pcDNA3.1/myc-His (Invitrogen, Carlsbad, CA,
USA). To generate a C-terminus tagged TRIP12 HECT
domain construct (TRIP12 HECT-HSV), the TRIP12
HECT domain cDNA sequence was cloned into pTriEx-1.1
(Novagen, Madison, WI, USA). SOX6 CC-myc and TRIP12
HECT-HSV (Figure 1C) were cotransfected into HEK293
cells using GenJet Plus DNA In Vitro Tranfection
Reagent (SignaGen Laboratories, Rockville, MD, USA)
and incubated in GM for 48 h. Cells were lysed in Buffer
A (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM
EDTA, 1% Nonidet P40) supplemented with protease
and phosphatase inhibitor cocktails (Thermo Scientific)
and clarified by centrifugation at 17,900g at 4°C for 10
min. IP was performed by incubating 500 μg of protein
(in 500 μl Buffer A) with 2 μg rabbit polyclonal antibody
targeting c-Myc (A00172, GenScript USA Inc., Piscataway,
NJ, USA) or HSV (A00624, GenScript USA Inc.) for 1 h at
4°C on a rocking platform. Anti-GST rabbit polyclonal
antibody (ab9085, Abcam) was used as a negative control.
The mixture was then supplemented with 20 μl Protein
A-agarose beads (Roche, Indianapolis, IN, USA) and incu-
bated overnight at 4°C on a rotating platform. Agarose
beads were washed five times with Buffer A, and 25 μl of
2X SDS-PAGE loading buffer was added to the washed
agarose beads to extract immunoprecipitated protein.
After incubating in boiling water for 5 min, extracted
protein was separated on a 4-15% gradient SDS-PAGE gel
and analyzed by Western blotting using the antibodies de-
scribed in the previous section. Co-IP of endogenous Sox6
and Trip12 proteins was performed using nuclear frac-
tions of differentiating C2C12 cells. Nuclear fractions were
obtained from C2C12 cells in 15-cm plates differentiated
for 48 h in DM using NE-PER Nuclear and Cytoplasmic
Extraction Reagents (Thermo Scientific). Protease and
phosphatase inhibitor cocktails (Thermo Scientific) were
added to appropriate reagents. Prior to IP, the NaCl con-
centration of nuclear fractions (~400 mM) was adjusted to
~150 mM using Buffer A without NaCl. IP and Western
blotting was performed with Rabbit TrueBlot Set
(Rockland Immunochemicals, Inc., Gilbertsville, PA, USA)
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clonal antibodies against Sox6 (ab30455, Abcam), TRIP12
(A301-814A, Bethyl Laboratories, Inc.), and GST (ab9085,
Abcam) according to the manufacturer’s instructions.
Immunoprecipitated protein was separated on a 7.5%
SDS-PAGE gel and was analyzed by Western blotting
using the same Sox6 and TRIP12 antibodies.
Tagged protein purification and in vitro ubiquitination
assay
Full-length human SOX6 cDNA [17] was cloned into
pcDNA3.1/myc-his to produce a His-tagged SOX6-myc
expression vector, while full-length human TRIP12 cDNA
(I.M.A.G.E. clone ID 40083165, ATCC, Manassas, VA,
USA) was cloned into pTriEx-1.1 to produce a His-tagged
TRIP12-HSV expression vector. HEK293 cells were
transfected with each of the tagged protein expression
vectors and grown for 48 h. Cells were harvested in
Buffer B (50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM
EGTA, 1% Nonidet P40, 0.3% sodium deoxycholate)
supplemented with 10 mM imidazole, protease, and
phosphatase inhibitor cocktails (Thermo Scientific), and
His-tagged SOX6 and TRIP12 proteins were purified at
4°C using MagneHis Protein Purification System
(Promega Corp., Madison, WI, USA) following the
manufacturer’s instructions. After purification, buffer
was changed to Buffer A (see the previous section)
supplemented with protease and phosphatase inhibitor
cocktails (Thermo Scientific) using Amicon Ultra-0.5,
Ultracel-30 Membrane, 30 kDa (EMD Millipore, Billerica,
MA, USA).
Ubiquitination of SOX6 by TRIP12 in vitro was deter-
mined using the purified proteins and substrates as de-
scribed previously [18] with minor modifications. Briefly,
100 ng of ubiquitin-activating enzyme E1 (Enzo Life
Sciences, Plymouth Meeting, PA, USA), 250 ng of E2
(UbcH5a, Enzo Life Sciences), 0.8 μg of ubiquitin (Enzo
Life Sciences), and 300 ng of purified SOX6 were mixed
in 20 μl reaction buffer (25 mM Tris-HCl, pH 7.5, 50
mM NaCl, 5 mM ATP, 10 mM MgCl2, 1 mM DTT, 1X
protease and phosphatase inhibitor cocktails) with or
without 3 μg of purified TRIP12 and were incubated at
37°C for 0, 1, and 2 h. Reactions were terminated by the
addition of 20 μl 2X SDS-PAGE loading buffer. Detec-
tion of ubiquitinated SOX6-myc protein was performed
by Western blot analysis using anti-c-Myc antibody
(R950-25, Invitrogen).
In vivo ubiquitination assay
HEK293 cells were plated in 60-mm culture dishes at a
density of 2 × 106 cells/plate and incubated for 24 h.
Cells were cotransfected with 0.5 μg of HA-Ub vector
(obtained from Dr. Aldrin V. Gomes at University of
California, Davis), 0.5 μg of Sox6-FLAG vector [mousefull-length Sox6 cDNA was cloned into pcDNA3.1/Zeo(+)
(Invitrogen) with a FLAG tag at the C-terminus], and the
indicated amount of TRIP12-HSV vector using 7.5 μl of
GenJet Plus DNA In Vitro Tranfection Reagent (SignaGen
Laboratories). pcDNA3.1/Zeo(+) and pTriEx-1.1 were
used as empty vectors for Sox6-FLAG and TRIP12-HSV
vectors, respectively. 24 h after incubation, 10 μM MG132
(EMD Millipore) was added to the medium to inhibit
the proteasome activity, and cells were incubated for
another 6 h. Cells were collected and lysed in Buffer B
(see the previous section) containing protease inhibitor
cocktail and 10 mM N-ethylmaleimide (an inhibitor for
deubiquitinating enzymes), and briefly sonicated using
Bioruptor (Diagenode, Denville, NJ, USA). Lysate was
cleared by centrifugation at 17,900g for 10 min at 4°C,
and protein was quantified using BCA Protein Assay
Reagent (Thermo Scientific). After pre-clearing 500 μg
of total protein using 2 μg of rat IgG2a, κ (BioLegend),
and 20 μl of Protein G-agarose beads (Roche), protein
samples were mixed with 5 μg of anti-DYKDDDDK
(FLAG) tag antibody, and the mixture was incubated for
2 h at 4°C on a rocking platform. Then 20 μl of Protein
G-agarose beads was added, and the mixture was incu-
bated overnight at 4°C on a rocking platform. Agarose
beads were washed five times with RIPA buffer, and 25
μl of 2X SDS-PAGE loading buffer was added to the
washed agarose beads to extract immunoprecipitated
protein. After incubating in boiling water for 5 min,
extracted protein was separated on a 7.5% SDS-PAGE
gel and was analyzed by Western blotting using anti-
HA antibody to detect polyubiquitinated Sox6-FLAG
protein. The membranes were subsequently incubated
with anti-DYKDDDDK (FLAG) tag antibody to detect
Sox6-FLAG protein. Input samples were also analyzed
using TRIP12 antibody to detect both endogenous
TRIP12 and overexpressed TRIP12-HSV proteins.siRNA experiments
C2C12 cells were plated in six-well plates at a density of
2 × 105 cells/well and incubated in GM for 24 h. siRNAs
(pre-designed DsiRNAs from Integrated DNA Technolo-
gies, Coralville, IA, USA) were transfected using 10 μl of
TransIT-TKO (Mirus Bio LLC, Madison, WI, USA) at
25 nM final concentration. Then 24 h after transfection,
cells were rinsed with PBS once and were incubated in
DM for 48 h.
To extract protein, cells were rinsed twice with ice-
cold PBS and were treated with trichloroacetic acid
(TCA) as described previously [19]. Briefly, cells were in-
cubated in 10% TCA for 30 min on ice and were collected
into 1.5-ml tubes. After centrifugation at 17,900g for 5
min at 4°C, cell pellets were briefly sonicated in 1X SDS-
PAGE loading buffer without bromophenol blue (BPB)
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hint of BPB and 2-ME (5%) were added, and the protein
samples were incubated in boiling water for 5 min. An
equal amount of protein was separated on a 7.5% or 4-
15% gradient SDS-PAGE gel and analyzed by Western
blotting using Sox6, TBP, TRIP12, and β-actin
antibodies.
For RNA extraction, cells were lysed in TRIzol reagent,
and total RNA was extracted using Direct-zol RNA
MiniPrep (Zymo Research, Irvine, CA, USA) with DNase
I treatment steps according to the manufacturer’s instruc-
tions. After synthesizing cDNA using High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems,
Carlsbad, CA, USA), quantitative PCR (qPCR) was
performed on ABI Prism 7900HT Sequence Detection
System (Applied Biosystems) using PrimeTime qPCR
Assays (Integrated DNA Technologies) or TaqMan Gene
Expression Assay (Applied Biosystems) and SensiFast
Probe Hi-ROX Kit (Bioline, Taunton, MA, USA). Results
were normalized to the β-actin (Actb) transcript level, and
all statistical analyses were performed using the two-tailed
Student's t-tests. For the time course experiments using
differentiating C2C12 cells, Huwe1 and Tbp were used as
reference genes instead of Actb because reference gene
analysis using GeNorm [20] revealed that the combination
of these two genes represented the most stably expressed
genes in differentiating C2C12 cells among eight genes
tested (Actb, Gapdh, Huwe1, Lrrc40, Rpl37a, Rpl41, Tbp,
and Ubb: data not shown). Additional analysis using
NormFinder [21] also showed that these two genes are
stably expressed in differentiating C2C12 cells (data not
shown). To use these two genes as a reference, raw thresh-
old cycle (CT) values of these two genes were averaged
according to the instructions of NormFinder, and the
mean CT values were used for further calculations. In-
formation on siRNAs, PrimeTime qPCR Assays, and
TaqMan Gene Expression Assay used is provided in
Additional file 1: Table S1.Treatment with cycloheximide and MG132
C2C12 cells were plated in six-well plates at a density of
3 × 105 cells/well and incubated in GM for 24 h. Cells
were rinsed with PBS once and incubated in DM for 24
h (for time-course experiments) or 48 h (for MG132
treatment). For time-course experiments, 100 μg/ml
cycloheximide (CHX) was added to DM, and cells were
incubated for 0, 6, 12, and 24 h. For MG132 treatment,
1 μM MG132 was added to DM together with 100 μg/
ml CHX, and cells were incubated for 6 h. As a negative
control, the same volume of dimethyl sulfoxide (DMSO)
was added. Protein was extracted using TCA as de-
scribed above and analyzed by Western blotting using
appropriate antibodies.Results
SOX6 interacts with TRIP12, an E3 ubiquitin ligase
expressed in muscle
During the formation of healthy muscle tissue, Sox6
functions to suppress transcription of a wide variety of
slow fiber-specific genes [9,12]. To identify the proteins
that interact with Sox6 and regulate the muscle fiber
phenotype, we performed yeast two-hybrid screening.
For the bait, the coiled-coil domain (CC domain) includ-
ing the leucine zipper (LZ) motif and glutamine-rich
domain (Q-box) of human SOX6 was used (Figure 1A)
[17]. This choice of bait was based on the following ra-
tionales: (1) the coiled-coil domain is a known protein-
protein interacting domain shown to interact with
multiple proteins [16,22-26], and (2) the amino acid
sequence and location of this domain are 100% con-
served between the mouse Sox6 and human SOX6
[17,27]. With this bait, we screened a cDNA library of
adult human heart, where SOX6 is moderately
expressed [17]. One of the candidates isolated was a clone
containing the C-terminus part of TRIP12 (Figure 1B).
Currently, what is known about this protein can be
summarized succinctly: TRIP12 belongs to the HECT
family of E3 ubiquitin ligases, a family characterized by
their highly conserved catalytic subunit located at the
C-terminus (HECT domain) [28]. Originally identified
as a protein that interacts with the ligand-binding do-
main of the thyroid hormone and retinoid receptors
[29], its function as an E3 ubiquitin ligase was reported
soon after for multiple targets [18,30-32]. Additionally,
it was shown to be essential for mammalian develop-
ment, as evidenced by a report showing that targeted in-
activation results in embryonic lethality in mice [33].
Although Trip12’s function in muscle has not been
reported, we hypothesized that the presumed regulation
of Sox6 activity by Trip12 would significantly affect
muscle differentiation and therefore we decided to
investigate.
To confirm the physical interaction between the SOX6
bait and the TRIP12 prey proteins, we first performed
Co-IP using lysates from HEK293 cells cotransfected
with expression vectors for the bait and prey tagged with
c-Myc and HSV epitopes at their C-termini, respectively
(Figure 1C). As shown in the upper panel of Figure 1D, the
SOX6 bait protein was successfully co-immunoprecipitated
with the TRIP12 prey protein when an antibody for
the TRIP12 prey (anti-HSV antibody) was used for IP.
However, the TRIP12 prey protein was not co-
immunoprecipitated when the SOX6 bait protein was
pulled down with a c-Myc antibody (Figure 1D, lower
panel). The same results were observed when the
SOX6 bait protein was fused with a FLAG tag at the
N-terminus and anti-FLAG antibody was used for IP
(data not shown). These results suggest that both the
An et al. Skeletal Muscle 2013, 3:11 Page 6 of 14
http://www.skeletalmusclejournal.com/content/3/1/11N- and C-termini of the SOX6 bait protein are physic-
ally blocked by the TRIP12 prey protein or unknown
protein(s) in HEK293 cells and therefore are not avail-
able for Co-IP of the TRIP12 prey protein by the
SOX6 bait.
Next, since little is known about Trip12 expression in
the mouse, we investigated expression of the Trip12 pro-
tein in adult mouse tissues using Western blotting. The
Trip12 band (the full-length mouse protein is approxi-
mately 224 kDa) was detected in various tissues includ-
ing skeletal muscle (Figure 2A). The specificity of the
antibody and the actual size of Trip12 band detected
were confirmed using Trip12 siRNA, which specifically
decreased the signal of the ~250 kDa band (Figure 2A).
Since Sox6 protein is expressed in both adult heart and
skeletal muscle [17,34] as well as in the nuclear fraction
of C2C12 cells (unpublished data), we examined whether
the endogenous Sox6 and Trip12 proteins also directly
interact. Co-IP using nuclear fractions of differentiating
C2C12 cells showed that endogenous Sox6 was co-
immunoprecipitated with endogenous Trip12 when
Trip12 antibody was used for IP (Figure 2B, left panel),
indicating physical interaction of these proteins in
C2C12 cells. However, endogenous Trip12 was not co-
immunoprecipitated when Sox6 antibody was used for
IP (Figure 2B, right panel), suggesting that the C-Figure 2 Trip12 protein expression in adult mouse tissues and intera
blot analysis was performed to determine Trip12 protein expression in adu
C12C12 samples, which contained 15 μg of protein per lane. Relevant prot
loading control. (B) Co-IP of endogenous Sox6 and Trip12 proteins using n
(15 μg) of pre-cleared nuclear protein. Antibodies used for pull down are li
below each panel. GST antibody was used as a negative control.terminus of endogenous Sox6 protein, where an epitope
for the Sox6 antibody used is located, is physically
blocked by Trip12 or unknown protein(s). Since the
pull-down using both tagged-proteins (Figure 1D) and
the endogenous proteins (Figure 2B) gave us similar re-
sults, i.e., the antibodies detecting Sox6 proteins did not
pull down Trip12 proteins, binding of Trip12 to Sox6
may result in masking a large surface area of the Sox6
protein.
TRIP12 polyubiquitinates Sox6
In the ubiquitin-proteasome system, E3 ubiquitin ligases
such as Trip12 facilitate the transfer of ubiquitin to spe-
cific substrates [13]. To examine whether Sox6 is a sub-
strate of TRIP12 E3 ligase activity and if this interaction
results in polyubiquitination of Sox6, we performed both
in vitro and an in vivo ubiquitination assay.
We first performed an in vitro ubiquitination assay
using purified recombinant proteins. The process of
ubiquitination of a target protein involves three enzymes,
a ubiquitin-activating enzyme, E1, a ubiquitin-conjugating
enzyme, E2, and a ubiquitin-protein ligase, E3 [13,28]. In
addition, E4 enzymes have recently been shown to en-
hance the polyubiquitination reaction in some cases [35].
To reconstitute the ubiquitination reaction, an equal
amount of purified SOX6-myc (substrate) was combinedction between endogenous Sox6 and Trip12 proteins. (A) Western
lt mouse tissues. Each lane contained 30 μg of protein except for the
ein size markers (kDa) are indicated to the left. β-actin was used as a
uclear fractions of differentiating C2C12 cells. Input lane contained 5%
sted under IP, and antibodies used for Western blot (WB) are indicated
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full-length TRIP12 E3 ligase (see the Methods section). As
shown in Figure 3A, addition of TRIP12 resulted in a
greater level of ubiquitination of SOX6-myc protein in a
time-dependent manner detected as an increasing upward
smear (lanes 4, 5, and 6). To test if this process occurred
in vivo, we performed in vivo ubiquitination assays.
HEK293 cells were cotransfected with the full-length
TRIP12-HSV, Sox6-FLAG, and HA-tagged ubiquitin
(HA-Ub) expression vectors. Immunoprecipitation was
performed with FLAG antibody to concentrate Sox6-
FLAG protein, followed by Western blotting using HA
antibody to detect ubiquitinated Sox6-FLAG protein.
As TRIP12 protein expression was doubled and tripled,
the amounts of high-molecular-weight products, which
are the sign of multiple additions of HA-Ub molecules,
also increased (Figure 3B), reflecting the addition of
multiple ubiquitin molecules to the Sox6-FLAG sub-
strate. As would be expected from a fixed pool of sub-
strate, the non-ubiquitinated Sox6-FLAG protein levels
decreased (Figure 3B), indicating that more Sox6-FLAG
was polyubiquitinated as Trip12 levels increased.
Knockdown of Trip12 in C2C12 myotubes results in a
concurrent increase in Sox6 protein levels and a decrease
of Myh7 transcription
Since polyubiquitination frequently leads to degradation
of the target substrate, we next tested the effect of
siRNA-induced Trip12 knockdown on Sox6 protein
levels in muscle cells. As shown in Figure 4A, in theFigure 3 TRIP12 ubiquitinates Sox6 in vitro and in vivo. (A) In vitro ubiq
the substrate and TRIP12 along with the combination of enzymes as indica
contain 3 μg of TRIP12-HSV. Western blot (WB) was performed using c-Myc
indicates non-specific bands detected in all reactions. (B) Sox6 is ubiquitina
DNAs encoding HA-Ub, Sox6-FLAG, and increasing amounts (0.5, 1, and 1.5
anti-DYKDDDDK (FLAG) antibody, and then processed for Western blotting
detected in all IP samples, although it is possible that these bands also con
~1 to 4 ubiquitin moieties) in Sox6-FLAG-transfected samples. The same m
antibody to detect Sox6-FLAG protein; 10 μg (2%) of input protein samples
antibody to detect both endogenous TRIP12 and overexpressed TRIP12-HSpresence of Trip12 siRNA, intensity of the ~224 kDa
band (full-length mouse Trip12) in C2C12 myotubes de-
creased to almost an undetectable level. Using this
Trip12 siRNA, the result of Trip12 inhibition on Sox6
protein levels was determined at a time point (48 h after
switching to DM) where Sox6 protein levels are known
to be decreasing in differentiating C2C12 myotube
cultures (see Additional file 2: Figure S1).
As can be seen in Figure 4B, reduction of Trip12 led
to a threefold increase in the amount of Sox6 protein,
whereas there was no change in protein levels of the nu-
clear transcription factor TATA-box binding protein
(Tbp) (used as a control). Therefore, Sox6 is a specific
substrate to Trip12, by which it is polyubiquitinated and
degraded. Whether a Trip12-mediated change in Sox6
protein level had any significant biological effects was
initially tested by analysis of changes in mRNA expres-
sion of Myh7, a direct Sox6 target gene [9,10]. When
Trip12 siRNA treatment effectively reduced Trip12
mRNA levels to approximately one third of the control
level (Figure 4C), Myh7 mRNA levels were reduced by 40%,
while Sox6 mRNA levels were unchanged (Figure 4C),
confirming the suppressive role of Sox6 on the Myh7
transcription at the post-transcriptional level.Sox6 protein is degraded by the 26S proteasome
The final stage of the ubiquitin-proteasome system is
degradation of the polyubiquitinated substrate by the
26S proteasome [13]. Therefore, we determined theuitination of SOX6 protein was performed using purified SOX6-myc as
ted in the figure (see the Methods section for details). Lanes 4–6
antibody to detect the degree of ubiquitination of Sox6-myc. Asterisk
ted by TRIP12 in vivo. HEK293 cells were cotransfected with plasmid
μg) of TRIP12-HSV, and lysates were immunoprecipitated (IP) with
(WB) using anti-HA antibody. Asterisk indicates non-specific bands
tain ubiquitinated Sox6-FLAG protein of lower molecular weights (with
embrane was subsequently incubated with anti-DYKDDDDK (FLAG)
(lysates) was also subjected to Western blotting using anti-TRIP 12
V proteins.
Figure 4 Trip12 controls Sox6 protein level in C2C12 cells. (A) siRNA-mediated knockdown of Trip12 resulted in an increase of Sox6 protein
levels in C2C12 cells. C2C12 cells were transfected with siRNA for either EGFP (negative control) or Trip12 in triplicate, and lysates were analyzed
by Western blotting using a 7.5% gel. (B) Densitometric analysis of the Western blot in (A) shows approximately 3-fold increase in the Sox6
protein level in Trip12 siRNA-treated cells, while the Tbp protein level was not affected. Data are normalized for those from EGFP siRNA-
transfected cells and represented as mean ± SD (n = 3). (C) Trip12 knockdown lowered mRNA level of Myh7, a known Sox6 target. Total RNA was
extracted from mock- or siRNA-transfected C2C12 cells, and mRNA levels of Trip12 and Myh7 were quantified by reverse transcription-quantitative
PCR (RT-qPCR). Data are normalized for those from EGFP siRNA-transfected cells and represented as mean ± SD (n = 3). **p < 0.005.
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tein levels.
A standard approach for examining proteasome-
mediated degradation of proteins is to use a combination
of a proteasome inhibitor such as MG132 and the pro-
tein synthesis inhibitor cycloheximide (CHX) [36]. Prior
to this experiment, the stability of the Sox6 protein
along with Trip12 and Tbp in C2C12 myotubes was de-
termined. C2C12 myotube cultures (induced for 24 h in
DM) were treated with CHX to stop new protein synthe-
sis, following which, the stability of the Sox6, Trip12,
and Tbp proteins was examined using Western blot.
After 24 h of CHX treatment, the myotubes looked
healthy and morphologically normal. As shown in
Figure 5A and summarized in Figure 5B, Sox6 and Tbp
appeared more stable than Trip12. The protein half-life
of Trip12 was estimated as ~9 h, whereas Sox6 protein’s
half-life was estimated as ~24 h (Figure 5B). The Tbpprotein appeared slightly more stable than Sox6
(Figure 5B). The Trip12 half-life estimated here is in
agreement with a similar turnover rate of the human
TRIP12 protein recently estimated in HeLa cells using a
proteomic approach [37].
Although the Sox6 half-life was found to be relatively
long (~24 h), we first tried a conventional proteasome
inhibitor (MG132) to examine proteasomal degradation
of Sox6. Since extended treatment with proteasome in-
hibitors is toxic to the cells [38], C2C12 cells were
treated with CHX in the absence or presence of MG132
only for 6 h, and the Sox6 protein level was examined by
Western blotting. As shown in Additional file 3: Figure
S2B, protein levels of myogenin, a short-lived transcrip-
tion factor [39], were reduced by CHX alone and were
recovered by MG132 addition, verifying the effect of
MG132 in our experimental condition. To conduct a
detailed examination of the response of Sox6 protein to
Figure 5 Sox6 is degraded by proteasome in C2C12 cells. (A) Time course of Trip12, Sox6, and Tbp protein levels in C2C12 cells in the
presence of cycloheximde (CHX) analyzed by Western blotting using a 4-15% gradient gel (n = 3). (B) Densitometric analysis of the Western blot
in (A). Band intensity of each protein was normalized to that of 0 h in CHX and represented as mean ± SD (n = 3). (C) Validation of Psmd1
knockdown by siRNA. Total RNA was extracted from mock- or siRNA-transfected C2C12 cells, and the mRNA level of Psmd1 (the gene encoding a
regulatory subunit of the 26S proteasome) was quantified by RT-qPCR. Data are normalized to EGFP siRNA-transfected cells and represented as
mean ± SD (n = 3). (D) A Western blot using a 7.5% gel showing an increase in the Sox6 protein level in Psmd1 siRNA-transfected C2C12 cells.
(E) Densitometric analysis of Western blotting results shows a ~4 fold increase in the Sox6 protein level in Psmd1 siRNA-treated C2C12 cells. A
smaller increase was observed for Tbp protein. Data are normalized for those from EGFP siRNA-transfected cells and represented as mean ± SD
(n = 3). (F) Psmd1 knockdown reduced the mRNA level of Myh7, a known target of Sox6. Data are normalized to EGFP siRNA-transfected cells and
represented as mean ± SD (n = 3). **p < 0.005.
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proteins of 75–100 kD (7.5%) and detected two closely
sized bands reacting with the Sox6 antibody (Additional
file 3: Figure S2B). Although MG132 did not change the
overall amount of the Sox6 proteins (total intensity of
the two bands; densitometric analysis also showed no
statistical difference between these samples: data not
shown), there was a significant increase in the upper
band along with a significant decrease in the lower band
(Additional file 3: Figure S2B), indicating that there is a
discrete shift in the Sox6 protein size in the presence of
MG132. We found that this size difference was caused
by phosphorylation of the Sox6 protein (Additional file 3:
Figure S2C). These results suggest a possibility that stabil-
ity of the Sox6 protein could be regulated by the balance
between phosphorylated and non-phosphorylated Sox6
proteins. We are currently investigating this possibility.
Because treatment with a conventional proteasomeinhibitor did not indicate proteasomal degradation of
Sox6 in an unambiguous manner as expected given its
long half-life, we next used a siRNA targeting a prote-
asome subunit to confirm proteasomal degradation of
Sox6. We chose to knockdown Psmd1, a subunit of the lid
domain of the 26S proteasome, because knockdown of
Psmd1 effectively inhibits proteasome activity without sig-
nificant toxicity [40]. Using Psmd1 siRNA, we successfully
obtained close to 50% reduction in Psmd1 mRNA levels
(Figure 5C). Under this condition, levels of Sox6 proteins
significantly increased (Figures 5D and 5E). As shown in
Figure 5F, Psdm1 siRNA treatment of C2C12 myotubes
also resulted in significant reduction of Myh7 mRNA
levels. Taken together, these results indicate that Sox6 is
degraded by the 26S proteasome and that inhibition of the
26S proteasome activity by siRNA resulted in increased
protein levels of Sox6 and increased suppression of its
target geneMyh7 in C2C12 myotubes.
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changes in expression of fast and slow MyHC genes in
C2C12 myotubes
Because both Trip12 knockdown and 26S proteasome
inhibition in myotube cultures resulted in increased
Sox6 protein levels (Figures 4A, 4B, 5D and 5E), and de-
creased mRNA levels of the Sox6 target Myh7 (Figures 4C
and 5F), we hypothesized that knockdown of Trip12
would result in fiber type-specific gene expression changes
opposite to those observed in the Sox6 KO mouse, i.e., an
increase in fast fiber-specific gene expression and a
decrease in slow fiber-specific gene expression [9,12].
To test this hypothesis, C2C12 myoblasts were
transfected with Trip12 siRNA or EGFP siRNA (a negative
control) and the mRNA levels of Myh7 (slow isoform),
myogenin (Myog: preferentially expressed in slow muscle
[41]), and Myh4 (fast MyHC-IIb isoform) were compared
in differentiating C2C12 myotube cultures. Brown et al.
[42] showed that in differentiating C2C12 cells, Myh7
increases after day 1 and then begins to decline after day
4; conversely, Myh4 begins to increase after day 4 in differ-
entiation medium. In this experiment, we normalized
mRNA expression levels in Trip12 siRNA transfected
myotubes against the control siRNA transfected
myotubes. Changes outside the control expression levels
are reflected as greater or lesser than 1. As shown in
Figure 6 and Additional file 4: Figure S3, transfection of
Trip12 siRNA caused a significant decrease in both Myh7Figure 6 Trip12 modulates mRNA levels of fiber-type-specific genes i
siRNA for either EGFP (negative control) or Trip12, and medium was switch
myotubes. Total RNA was then extracted every 24 h, and the time course o
myogenin (Myog) were quantified by RT-qPCR using Huwe1 and Tbp as ref
normalized for those from EGFP siRNA-transfected cells and represented as
Trip12 siRNA-transfected samples is expressed as 1 on the graph. *p < 0.05and Myog mRNA levels as well as a significant increase in
Myh4 (day 4 in DM), a mirror image of their expression
patterns in the Sox6 knockout muscle [9,12], suggesting
that Trip12 regulation of Sox6 can have a fundamental
impact on the fiber type identity.
Discussion
We have previously reported that a primary mechanism
in fiber type-specific gene expression involves the coor-
dinated suppression of hundreds of slow fiber-specific
genes by the transcription factor Sox6 [9]. Muscle-
specific knockout of Sox6 results in a dramatic increase
in slow MyHC-β (Myh7) expression coupled with a sig-
nificant decrease in fast MyHC-IIb (Myh4) expression
[9,12]. Muscle-specific loss of Sox6 effectively shifts
muscle tissue into the slower fiber phenotype leading to
the prediction that regulation of Sox6 activity in skeletal
muscle could be a focal point of fiber type differenti-
ation. Our present study expands our investigations into
the mechanisms of fiber type determination by looking
at the regulation of Sox6 by the ubiquitin-proteasome
pathway. The identification of the relatively unexplored
E3 ligase Trip12 as a Sox6 partner protein led us to in-
vestigate the impact of Trip12 activity on cellular Sox6
protein levels. Using siRNA of Trip12, we were able to
show that the knockdown of Trip12 expression in
C2C12 myotubes resulted in (1) an increase in Sox6 pro-
tein levels, (2) the simultaneous downregulation of bothn differentiating C2C12 cells. C2C12 cells were transfected with
ed to DM 24 h after transfection to induce differentiation into
f mRNA levels of Trip12, Myh4 (MyHC-IIb), Myh7 (MyHC-I/β), and
erence genes (see the Methods section for details). Data are
mean ± SD (n=3). No expression change between EGFP siRNA- and
, **p < 0.01, ***p < 0.005.
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myogenin, and (3) upregulation of Myh4 (fast), thus
suggesting that Trip12, by controlling Sox6 protein
levels, plays a critical role in regulating muscle fiber
type-specific gene expression. This observation signifi-
cantly expands the role of E3 ligases in skeletal muscle
beyond their traditionally conceived role in atrophy and,
possibly, into the realm of fundamental developmental
processes in the muscle.
The role of Sox6 as a transcriptional suppressor of
slow fiber-specific isoform genes in skeletal muscle has
been reported in mice and zebrafish [9,10,43]. These re-
ports indicate that the function of Sox6 during skeletal
muscle development is likely conserved through verte-
brate evolution since the loss of Sox6 activity in both
species results in the increased mRNA expression of
slow fiber-specific genes [9,12,43]. Sox6 is also expressed
in the adult heart at a moderate level [17,34]. During
heart development, it has been shown that Sox6 is
expressed at a high level in proliferating cardiomyocyte
progenitor cells, and a reduced Sox6 expression level
causes the progenitors to exit from the cell cycle and
differentiate [44]. Therefore, control of the cellular levels
of the Sox6 protein is potentially a vital mechanism to
regulate development of both cardiac and skeletal
muscle.
To identify Sox6 interacting proteins, we performed
yeast two-hybrid screening and identified TRIP12, an E3
ubiquitin ligase, as a SOX6-interacting protein. In adult
mouse tissues, the Trip12 protein is expressed highest in
testis and moderately in both skeletal muscle and the
heart (Figure 2A). Endogenous Trip12 and Sox6 proteins
in C2C12 cells directly interact (Figure 2B), and Trip12
polyubiquitinates Sox6 both in vitro and in vivo (Figure 3).
Ubiquitination is a complex and multifaceted regulatory
system involving the modification of a target protein by
addition of either one or multiple ubiquitin molecules
leading to many different outcomes depending on the
number of ubiquitins added or the topology of the ubiqui-
tin chain [14,45]. The addition of one or more ubiquitin
molecules to a protein is a multistep process involving at
least three ubiquitin enzymes, E1, E2 and E3. In this art-
icle, we focused on Trip 12, an E3 ubiquitin ligase, which
polyubiquitinates Sox6. The E3 ligases’ role in the
ubiquitination chain comes at the end of a multistep
process, where it functions to attach one or more ubiqui-
tin molecules to a specific target protein [13,45].
Currently, it is estimated that more than 1,000 distinct E3
ligase genes are encoded in the human genome [13]. The
majority of these are classified into the RING family of E3
ligases with a much smaller family of genes belonging to
the HECT family, of which Trip12 is a member [28,46].
The HECT domain consists of approximately 350 amino
acids encoding the E3 ligase catalytic domain. It is locatedat the carboxyl terminus and is evolutionarily highly
conserved [28,45]. Amino acid sequences lying outside of
the HECT domain vary among the family members lead-
ing to suggestions that this N-terminus part of the protein
primarily determines substrate specificity [28,46]. In the
ubiquitination of target proteins, many E3 ubiquitin li-
gases possess the capability of polyubiquitination, while
some are only capable of monoubiquitination when alone,
and require an E4 ligase for attachment of additional
ubiquitin molecules [35]. Our in vitro ubiquitination assay
results show that TRIP12 can polyubiquitinate Sox6 in the
absence of an E4 (Figure 3A). Interestingly, the length of
smear bands detected was different between in vitro and
in vivo: while in vitro ubiquitination assay showed smear
bands up to ~250 kDa (Figure 3A), a higher molecular
weight of smear bands was detected in in vivo
ubiquitination assay (Figure 3B). These results suggest that
there might be additional factor(s) in vivo (e.g., an E4 lig-
ase), which assists further elongation of polyubiquitin
chains by Trip12. TRIP12, a more recently recognized E3
ubiquitin ligase, was identified based on its sequence
homology to the yeast UFD4 E3 ubiquitin ligase [32]. The
E3 ligase activity of TRIP12 HECT domain was subse-
quently demonstrated [18]. The TRIP12 substrates known
to date include APP1-BP1 (amyloid beta precursor
protein-binding protein 1) [32], the SWI/SNF chromatin
remodeling complex subunit BAF57 [31], the tumor sup-
pressor protein ARF [30], and the RING finger E3 ligase
RNF168 [47]. Our current report adds the transcription
factor Sox6 as a TRIP12 substrate polyubiquitinated in
muscle cells. Since the TRIP12 clone identified by yeast
two-hybrid screening contained only the HECT domain
(Figure 1B) and the TRIP12 HECT domain alone could
interact with the SOX6 coiled-coil domain (Figure 1D), we
speculate that the HECT domain is the minimal necessary
requirement for TRIP12 to recognize SOX6 as a substrate.
In fact, the dual role of the TRIP12 HECT domain (E3
ligase catalytic activity and the substrate recognition) has
been previously demonstrated [18]. Park and colleagues
reported that the HECT domain of TRIP12, but not
UBE3A (E6-AP), could recognize and ubiquitinate an E3
ligase substrate on its own [32]. Our current result indi-
cates that this observation holds for the recognition of
SOX6 as a substrate by TRIP12. The ability of the HECT
domain to function as a ligase catalytic domain as well as
a substrate recognition module could be a unique trait for
the TRIP12 HECT domain, which will be tested in the
future as more information becomes available for the
other HECT domain E3 ligases.
The addition of one or more ubiquitin molecules to a
target protein lends a tremendous flexibility to the cellu-
lar fate of that protein. Depending on the ubiquitin code
(for review, see Komander et al. [45]), the activity, loca-
tion, partners and even the protein’s survival can be
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TRIP12 and is degraded by the 26S proteasome. In con-
trast to other critical myogenic regulatory factors such as
MyoD or myogenin, the half-life of Sox6 is surprisingly
long (~24 h). Half-lives of MyoD, Myf5, and myogenin
have been reported as 0.8-1.0 h, <1.0 h, and ~1.0 h,
respectively [39,48,49]. The stable nature of Sox6 may
reflect its function in muscle development; Sox6 plays a
role in specification of myotube phenotype by regulating
fiber type differentiation and is expressed at high levels in
myotubes [10]. Therefore, the relative stability of Sox6
may be necessary for stably maintaining the fiber pheno-
type of myotubes. The ubiquitously expressed nuclear
protein Tbp is also stable, supporting the correlation of
protein stability with maintenance of gene expression.
In muscle, the overall stability of a multigene regulator
such as Sox6 lends stability to a phenotype such as
muscle fiber type, but this same stability could quickly
become a hindrance when external signals demand a
fiber type shift. Thus, the polyubiquitination of Sox6 by
the Trip12 E3 ligase leading to its degradation would
allow for a swift response in the face of changing work-
loads of the muscle. Therefore, Trip12 likely functions as
a pivot point in fiber type transition, altering the balance
between slow and fast fiber gene expression. To date,
two other mechanisms regulating Sox6 protein activities
within the cells have been reported: regulation by
microRNA and sumoylation. The Sox6 mRNA has a
long (~5 kb) 3’-UTR sequence, which contains multiple
microRNA seed sequences [22]. MicroRNAs are
expressed in a cell type-specific manner and are known
to regulate the protein levels of cell type-specific genes
[50]. miR-499 is known to target the Sox6 mRNA and
suppresses Sox6 protein expression in skeletal muscle
[51-54] and in differentiating cardiomyocytes [44]. In the
central nervous system, it has been shown that miR-219
targets Sox6 in oligodendrocytes and induces the ter-
minal differentiation of oligodendrocytes [55,56]. Post-
translational modification can also control the function
of a protein. In the case of Sox6, it has been shown that
SUMO (small ubiquitin-related modifier) reduces the
binding affinity of Sox6 to DNA, thus changing its tran-
scriptional activity [57].
In the current report, we have demonstrated that
Trip12 ubiquitinates the Sox6 protein, Sox6 is degraded
by the 26S proteasome, and in both these instances, the
expression of Sox6 target genes are affected. Since skel-
etal muscle is highly plastic in nature and in transitions
between the slow and fast fiber types [58], the speedy re-
moval of relevant transcription factors (e.g., Sox6) via
the ubiquitin-proteasome system could allow for a rapid
response to external cues.
Taken together, regulation of Sox6 protein activity, both
post-transcriptional and post-translational, has criticaloutcomes on differentiation of various cell types. Although
Sox6 mRNA is transcribed in multiple tissues at moderate
to high levels [17,34], its role as a transcription factor is
quite distinct in different cell types [22]. This is because,
in part, cell type-specific Sox6 functions are dictated by its
regulatory co-factors [22,24]. To achieve developmental
stage-specific functions, however, close monitoring of the
Sox6 protein expression level is also critical. In light of
this, the ubiquitin-proteasome system mediated degrad-
ation of the Sox6 protein likely plays a crucial role in tem-
poral regulation of the Sox6 protein level during
development. It is possible that a different set of E3 ligases
catalyzes ubiquitination of the Sox6 protein depending on
different cellular environments (e.g.. different cell types) or
different signals. Therefore, further uncovering of the
ubiquitin-proteasome regulation of transcription factors
will enrich our understanding of the multi-layered mecha-
nisms of transcriptional regulation during development.
Conclusions
We have shown here that Trip12, a HECT domain E3
ubiquitin ligase, targets Sox6, a suppressor for slow
fiber-specific genes. In addition, we showed that Trip12
is involved in regulation of the fast MyHC isoform gene
expression. Based on our current data, we propose that
in skeletal muscle, E3 ligases have a significant role in
regulating fiber type-specific gene expression, expanding
their functional importance in muscle beyond their well-
established role in atrophy.
Additional files
Additional file 1: Table S1. siRNAs, PrimeTime qPCR Assays, and
TaqMan Gene Expression Assay used in the experiments.
Additional file 2: Figure S1. Temporal changes in Sox6 expression
level in differentiating C2C12 cells. (A) RNA was prepared every 24 h
from C2C12 cells grown in DM at the indicated time. RT-qPCR for Sox6
was performed using TaqMan Gene Expression Assays (Applied
Biosystems). Gapdh expression level was used to normalize data. Fold
increase in mRNA levels (0 h in DM = 1) was calculated at each time
point. Each data set represents four independent RT-qPCR experiments
(mean ± SD). (B) Crude protein extract prepared from differentiating
C2C12 cells (0, 24, 48, and 72 h in DM) was separated on a 7% SDS-PAGE
gel (100 μg per well), and Western blotting was performed using Sox6
antibody. A ~90 kDa Sox6 band was detected in all C2C12 cell extracts.
The highest Sox6 protein expression was observed at 24 h in DM and
then rapidly dropped close to the 0 h level at 48 h in DM. β-actin was
used as a loading control.
Additional file 3: Figure S2. MG132 treatment shifted the intensity of
the two Sox6 bands in differentiating C2C12 cells. (A) A procedure for
MG132 experiments. C2C12 cells were seeded in six-well plates at a
density of 3 × 105 cells/well and incubated in GM for 24 h. Cells were
rinsed with PBS once and incubated in DM. After 48 h, 100 μg/ml CHX
and 1 μM MG132 or the same volume of DMSO (with which MG132
stock solution was prepared) were added to DM, and cells were
incubated for another 6 h before Western blotting. (B) Western blots of
MG132-treated cells. Three independent samples were prepared for each
treatment. Tbp was used as a loading control. (C) Phosphatase treatment
of C2C12 nuclear protein; 5 μg of nuclear protein prepared from
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http://www.skeletalmusclejournal.com/content/3/1/11differentiating C2C12 cells without phosphatase inhibitor cocktail was
treated with 10 units of calf intestinal alkaline phosphatase (CIP) in the
absence or presence of phosphatase inhibitor cocktail (PIC) for 10 min at
37°C and analyzed by Western blotting using a 7.5% gel. Positions of two
Sox6 bands, which are always seen on 7.5% gels but not on 4-15%
gradient gels, are indicated. CIP treatment shifted the position of Sox6
band from upper to lower size, indicating that the upper band consists
of a phosphorylated form of Sox6.
Additional file 4: Figure S3. Relative mRNA levels of fiber-type-specific
genes shown in Figure 6. Relative mRNA levels against reference genes
(Huwe1 and Tbp) were calculated using the formula 2-ΔCt and
represented as mean ± SD (n=3).
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